• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

按皮质类固醇使用情况分层的新型冠状病毒2型所致院内死亡率

In-hospital mortality in SARS-CoV-2 stratified by the use of corticosteroid.

作者信息

Alotaibi Naser, Alroomi Moudhi, Aboelhassan Wael, Hussein Soumoud, Rajan Rajesh, AlNasrallah Noor, Al Saleh Mohammad, Ramadhan Maryam, Zhanna Kobalava D, Pan Jiazhu, Malhas Haya, Abdelnaby Hassan, Almutairi Farah, Al-Bader Bader, Alsaber Ahmad, Abdullah Mohammed

机构信息

Department of Medicine, Al Adan Hospital, Hadiya, Kuwait.

Department of Infectious Diseases, Infectious Diseases Hospital, Shuwaikh Medical Area, Kuwait.

出版信息

Ann Med Surg (Lond). 2022 Aug;80:104105. doi: 10.1016/j.amsu.2022.104105. Epub 2022 Jun 29.

DOI:10.1016/j.amsu.2022.104105
PMID:35784615
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9239918/
Abstract

OBJECTIVE

To investigate COVID-19 related mоrtаlity according to the use of corticosteroid therapy.

DESIGN

Retrospective cohort study.

SETTING

Two tertiary hospitals in Kuwait.

PARTICIPANTS

Overall, 962 patients with confirmed SARS-CoV-2 infection, were stratified according to whether they were treated with corticosteroids (dexamethasone or methylprednisolone). The mean age of the patients was 50.2 ± 15.9 years and 344/962 (35.9%) were female.

MAIN OUTCOME MEASURES

In-hospital mortality and cumulative all-cause mortality.

RESULTS

Compared to non-corticosteroid therapy patients, corticosteroid therapy patients had a higher prevalence of hypertension, diabetes mellitus, cardiovascular disease, chronic lung disease, and chronic kidney disease; a longer hospital stay (median [IQR]: 17.0 [5.0-57.3] days vs 14.0 [2.0-50.2] days); and a higher in-hospital mortality (51/199 [25.6%] vs 36/763 [4.7%]). Logistic regression analysis showed a higher in-hospital mortality in the corticosteroid group (adjusted odds ratio [aOR]: 4.57, 95% confidence interval [CI]: 2.64-8.02, p < 0.001). Cox proportional hazards regression showed that corticosteroid use was a significant predictor of mortality (hazard ratio [HR]: 3.96, p < 0.001).

CONCLUSIONS

In-hospital mortality in patients with SARS-CoV-2 on corticosteroid therapy was 4.6 times higher than in those without corticosteroid therapy.

摘要

目的

根据皮质类固醇疗法的使用情况调查新型冠状病毒肺炎（COVID-19）相关死亡率。

设计

回顾性队列研究。

地点

科威特的两家三级医院。

参与者

总体而言，962例确诊感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的患者，根据是否接受皮质类固醇（地塞米松或甲泼尼龙）治疗进行分层。患者的平均年龄为50.2±15.9岁，344/962（35.9%）为女性。

主要观察指标

住院死亡率和累积全因死亡率。

结果

与未接受皮质类固醇治疗的患者相比，接受皮质类固醇治疗的患者高血压、糖尿病、心血管疾病、慢性肺病和慢性肾病的患病率更高；住院时间更长（中位数[四分位间距]：17.0[5.0 - 57.3]天对14.0[2.0 - 50.2]天）；住院死亡率更高（51/199[25.6%]对36/763[4.7%]）。逻辑回归分析显示皮质类固醇组的住院死亡率更高（调整优势比[aOR]：4.57，95%置信区间[CI]：2.64 - 8.02，p<0.001）。Cox比例风险回归显示使用皮质类固醇是死亡率的显著预测因素（风险比[HR]：3.96，p<0.001）。

结论

接受皮质类固醇治疗的SARS-CoV-2患者的住院死亡率比未接受皮质类固醇治疗的患者高4.6倍。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bdd5/9284379/bb145b2b100b/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bdd5/9284379/c8a275189a10/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bdd5/9284379/bb145b2b100b/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bdd5/9284379/c8a275189a10/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bdd5/9284379/bb145b2b100b/gr2.jpg

相似文献

1
In-hospital mortality in SARS-CoV-2 stratified by the use of corticosteroid.按皮质类固醇使用情况分层的新型冠状病毒2型所致院内死亡率
Ann Med Surg (Lond). 2022 Aug;80:104105. doi: 10.1016/j.amsu.2022.104105. Epub 2022 Jun 29.
2
In-hospital mortality in SARS-CoV-2 stratified by sex diffrences: A retrospective cross-sectional cohort study.按性别差异分层的新型冠状病毒肺炎住院死亡率：一项回顾性横断面队列研究。
Ann Med Surg (Lond). 2022 Jul;79:104026. doi: 10.1016/j.amsu.2022.104026. Epub 2022 Jun 20.
3
Ferritin level: A predictor of severity and mortality in hospitalized COVID-19 patients.铁蛋白水平：预测住院 COVID-19 患者的严重程度和死亡率。
Immun Inflamm Dis. 2021 Dec;9(4):1648-1655. doi: 10.1002/iid3.517. Epub 2021 Aug 26.
4
In-hospital mortality in SARS-CoV-2 stratified by gamma-glutamyl transferase levels.根据谷氨酰转移酶水平对 SARS-CoV-2 进行分层的住院死亡率。
J Clin Lab Anal. 2022 Apr;36(4):e24291. doi: 10.1002/jcla.24291. Epub 2022 Mar 9.
5
In-hospital mortality in SARS-CoV-2 stratified by hemoglobin levels: A retrospective study.按血红蛋白水平分层的新型冠状病毒肺炎住院死亡率：一项回顾性研究。
EJHaem. 2021 May 5;2(3):335-339. doi: 10.1002/jha2.195. eCollection 2021 Aug.
6
Risk Factors Associated With Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy, Italy.意大利伦巴第地区重症监护病房中 COVID-19 患者死亡的相关危险因素。
JAMA Intern Med. 2020 Oct 1;180(10):1345-1355. doi: 10.1001/jamainternmed.2020.3539.
7
Low-dose corticosteroid treatment in septic shock: a propensity-matching study.脓毒性休克的低剂量皮质类固醇治疗：一项倾向匹配研究。
Crit Care Med. 2014 Nov;42(11):2333-41. doi: 10.1097/CCM.0000000000000518.
8
The outcomes of patients with diabetes mellitus in The Philippine CORONA Study.菲律宾 CORONA 研究中糖尿病患者的结局。
Sci Rep. 2021 Dec 24;11(1):24436. doi: 10.1038/s41598-021-03898-1.
9
Clinical Characteristics and Risk Factors for Mortality of COVID-19 Patients With Diabetes in Wuhan, China: A Two-Center, Retrospective Study.中国武汉 COVID-19 合并糖尿病患者的临床特征和死亡危险因素：一项两中心回顾性研究。
Diabetes Care. 2020 Jul;43(7):1382-1391. doi: 10.2337/dc20-0598. Epub 2020 May 14.
10
Multicentre cohort study of acute cholecystitis management during the COVID-19 pandemic.多中心队列研究：COVID-19 大流行期间急性胆囊炎的治疗管理。
Eur J Trauma Emerg Surg. 2021 Jun;47(3):683-692. doi: 10.1007/s00068-021-01631-1. Epub 2021 Mar 19.

引用本文的文献

1
Correlates of Coronavirus Disease 2019 Inpatient Mortality at a Southern California Community Hospital With a Predominantly Hispanic/Latino Adult Population.南加州一家以西班牙裔/拉丁裔成年人口为主的社区医院中2019冠状病毒病住院死亡率的相关因素。
Open Forum Infect Dis. 2023 Jan 10;10(1):ofad011. doi: 10.1093/ofid/ofad011. eCollection 2023 Jan.

本文引用的文献

1
In-hospital mortality in SARS-CoV-2 stratified by gamma-glutamyl transferase levels.根据谷氨酰转移酶水平对 SARS-CoV-2 进行分层的住院死亡率。
J Clin Lab Anal. 2022 Apr;36(4):e24291. doi: 10.1002/jcla.24291. Epub 2022 Mar 9.
2
Risk Factors for Mortality in Patients with COVID-19: The Kuwait Experience.COVID-19 患者死亡的危险因素：科威特经验。
Med Princ Pract. 2022;31(2):180-186. doi: 10.1159/000522166. Epub 2022 Jan 26.
3
STROCSS 2021: Strengthening the reporting of cohort, cross-sectional and case-control studies in surgery.
STROCSS 2021：加强外科学队列研究、横断面研究和病例对照研究报告规范。
Int J Surg. 2021 Dec;96:106165. doi: 10.1016/j.ijsu.2021.106165. Epub 2021 Nov 11.
4
Ferritin level: A predictor of severity and mortality in hospitalized COVID-19 patients.铁蛋白水平：预测住院 COVID-19 患者的严重程度和死亡率。
Immun Inflamm Dis. 2021 Dec;9(4):1648-1655. doi: 10.1002/iid3.517. Epub 2021 Aug 26.
5
In-hospital mortality in SARS-CoV-2 stratified by hemoglobin levels: A retrospective study.按血红蛋白水平分层的新型冠状病毒肺炎住院死亡率：一项回顾性研究。
EJHaem. 2021 May 5;2(3):335-339. doi: 10.1002/jha2.195. eCollection 2021 Aug.
6
In-hospital mortality in SARS-CoV-2 stratified by serum 25-hydroxy-vitamin D levels: A retrospective study.血清 25-羟维生素 D 水平分层的 SARS-CoV-2 院内死亡率：一项回顾性研究。
J Med Virol. 2021 Oct;93(10):5880-5885. doi: 10.1002/jmv.27133. Epub 2021 Jun 20.
7
Severity and Mortality Associated with Steroid Use among Patients with COVID-19: A Systematic Review and Meta-Analysis.新型冠状病毒肺炎患者使用类固醇的严重程度和死亡率：一项系统评价和荟萃分析。
Interdiscip Perspect Infect Dis. 2021 May 6;2021:6650469. doi: 10.1155/2021/6650469. eCollection 2021.
8
Timing of corticosteroids impacts mortality in hospitalized COVID-19 patients.皮质类固醇的使用时机影响住院 COVID-19 患者的死亡率。
Intern Emerg Med. 2021 Sep;16(6):1593-1603. doi: 10.1007/s11739-021-02655-6. Epub 2021 Feb 5.
9
Impact of Corticosteroids in Coronavirus Disease 2019 Outcomes: Systematic Review and Meta-analysis.皮质类固醇对 2019 冠状病毒病结局的影响：系统评价和荟萃分析。
Chest. 2021 Mar;159(3):1019-1040. doi: 10.1016/j.chest.2020.10.054. Epub 2020 Oct 28.
10
Addition of Tocilizumab to the Standard of Care Reduces Mortality in Severe COVID-19: A Systematic Review and Meta-Analysis.在标准治疗中添加托珠单抗可降低重症 COVID-19 的死亡率：一项系统评价和荟萃分析。
Front Med (Lausanne). 2020 Oct 2;7:586221. doi: 10.3389/fmed.2020.586221. eCollection 2020.